- Home
- BIIB vs STT Comparison
BIIB vs STT Comparison
Compare BIIB & STT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIIB
- STT
- Stock Information
- Founded
- BIIB 1978
- STT 1792
- Country
- BIIB United States
- STT United States
- Employees
- BIIB N/A
- STT N/A
- Industry
- BIIB Biotechnology: Pharmaceutical Preparations
- STT Major Banks
- Sector
- BIIB Health Care
- STT Finance
- Exchange
- BIIB Nasdaq
- STT Nasdaq
- Market Cap
- BIIB 25.1B
- STT 29.4B
- IPO Year
- BIIB 1991
- STT N/A
- Fundamental
- Price
- BIIB $149.53
- STT $98.89
- Analyst Decision
- BIIB Buy
- STT Buy
- Analyst Count
- BIIB 26
- STT 14
- Target Price
- BIIB $248.00
- STT $97.71
- AVG Volume (30 Days)
- BIIB 1.6M
- STT 2.5M
- Earning Date
- BIIB 02-11-2025
- STT 01-17-2025
- Dividend Yield
- BIIB N/A
- STT 3.06%
- EPS Growth
- BIIB 10.05
- STT N/A
- EPS
- BIIB 11.06
- STT 6.30
- Revenue
- BIIB $9,607,500,000.00
- STT $12,548,000,000.00
- Revenue This Year
- BIIB N/A
- STT N/A
- Revenue Next Year
- BIIB N/A
- STT $3.45
- P/E Ratio
- BIIB $13.47
- STT $15.75
- Revenue Growth
- BIIB N/A
- STT 4.38
- 52 Week Low
- BIIB $145.07
- STT $70.20
- 52 Week High
- BIIB $268.30
- STT $101.91
- Technical
- Relative Strength Index (RSI)
- BIIB 31.81
- STT 54.71
- Support Level
- BIIB $145.07
- STT $94.83
- Resistance Level
- BIIB $149.92
- STT $99.35
- Average True Range (ATR)
- BIIB 3.57
- STT 2.09
- MACD
- BIIB 0.18
- STT -0.27
- Stochastic Oscillator
- BIIB 22.27
- STT 57.34
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.
About STT State Street Corporation
State Street is a leading provider of financial services, including investment servicing, investment management, and investment research and trading. With approximately $47 trillion in assets under custody and administration and $4.7 trillion assets under management as of Dec. 31, 2023, State Street operates globally in more than 100 geographic markets and employs more than 46,000 worldwide.